EUVIMEDEUVIMED entdecken
Open Access

Soluble adenylyl cyclase contributes to imiquimod‐mediated inflammation and is a potential therapeutic target in psoriasis

Jaewon You, Michael D Reilly, Mahmoud Eljalby, Rohan Bareja, Maftuna Yusupova, Nikki S Vyas, Jakyung Bang, Wanhong Ding, Garrett Desman, Lloyd S Miller, Olivier Elemento, Richard D Granstein und 1 weitere

Experimental Dermatology · 2023

DOI: 10.1111/exd.14811 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Experimental Dermatology, 2023. Verfasst von Jaewon You und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Weill Cornell Medicine, New York City, New York, USA. Hauptthemen laut MEDLINE: Adenylyl Cyclases, Eczema, Psoriasis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NCI NIH HHS, National Institute of Arthritis and Musculoskeletal and Skin Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cyclic AMP (cAMP) has a key role in psoriasis pathogenesis, as indicated by the therapeutic efficacy of phosphodiesterase inhibitors that prevent the degradation of cAMP. However, whether soluble adenylate cyclase (sAC) (encoded by the ADCY10 gene), which is an important source for cAMP, is involved in Th17 cell‐mediated inflammation or could be an alternative therapeutic target in psoriasis is unknown. We have utilized the imiquimod model of murine psoriasiform dermatitis to address this question. Adcy10 −/− mice had reduced erythema, scaling and swelling in the skin and reduced CD4+ IL17+ cell numbers in the draining lymph nodes, compared with wild‐type mice after induction of psoriasiform dermatitis with imiquimod. Keratinocyte‐specific knock out of Adcy10 had no effect on imiquimod‐induced ear swelling suggesting keratinocyte sAC has no role in imiquimod‐induced inflammation. During Th17 polarization in vitro, naive T cells from Adcy10 −/− mice exhibited reduced IL17 secretion and IL‐17+ T‐cell proliferation suggesting that differentiation into Th17 cells is suppressed without sAC activity. Interestingly, loss of sAC did not impact the expression of Th17 lineage‐defining transcription factors (such as Rorc and cMaf ) but rather was required for CREB‐dependent gene expression, which is known to support Th17 cell gene expression. Finally, topical application of small molecule sAC inhibitors (sACi) reduced imiquimod‐induced psoriasiform dermatitis and Il17 gene expression in the skin. Collectively, these findings demonstrate that sAC is important for psoriasiform dermatitis in mouse skin. sACi may provide an alternative class of topical therapeutics for Th17‐mediated skin diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenylyl CyclasesEczemaPsoriasisAnimalsMiceDisease Models, AnimalImiquimodInflammationSkinTh17 Cells

Stichwörter der Autor:innen

Th17cAMPimiquimodsoluble adenylyl cyclase

Substanzen

Adenylyl CyclasesImiquimodAdcy10 protein, mouse

Autor:innen und Institutionen

  • Department of Dermatology, Weill Cornell Medicine, New York City, New York, USA.
  • Englander Institute of Precision Medicine, Weill Cornell Medicine, New York City, New York, USA.
  • Departments of Pathology and Dermatology, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.
  • ProHEALTH Care Associates, OptumCare, New Hyde Park, New York, USA.
  • Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Immunology, Janssen Research and Development, Spring House, Pennsylvania, USA.

ORCID-Profile: Jonathan H Zippin

Förderung

  • NIAMS NIH HHS
  • NCI NIH HHS
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases
  • Pfizer
  • National Cancer Institute

Zitieren

APA

You, J., Reilly, M. D., Eljalby, M., Bareja, R., Yusupova, M., Vyas, N. S., Bang, J., Ding, W., Desman, G., Miller, L. S., Elemento, O., Granstein, R. D., & Zippin, J. H. (2023). Soluble adenylyl cyclase contributes to imiquimod‐mediated inflammation and is a potential therapeutic target in psoriasis. Experimental Dermatology. https://doi.org/10.1111/exd.14811

Vancouver

You J, Reilly MD, Eljalby M, Bareja R, Yusupova M, Vyas NS, et al. Soluble adenylyl cyclase contributes to imiquimod‐mediated inflammation and is a potential therapeutic target in psoriasis. Experimental Dermatology. 2023. doi:10.1111/exd.14811

BibTeX
@article{You2023,
  author = {You, Jaewon and Reilly, Michael D and Eljalby, Mahmoud and Bareja, Rohan and Yusupova, Maftuna and Vyas, Nikki S and Bang, Jakyung and Ding, Wanhong and Desman, Garrett and Miller, Lloyd S and Elemento, Olivier and Granstein, Richard D and Zippin, Jonathan H},
  title = {Soluble adenylyl cyclase contributes to imiquimod‐mediated inflammation and is a potential therapeutic target in psoriasis},
  journal = {Experimental Dermatology},
  year = {2023},
  doi = {10.1111/exd.14811}
}
Kostenlos starten →